

Datasheet: HCA232P

Description:	HUMAN ANTI ADALIMUMAB (DRUG/TARGET COMPLEX):HRP
Specificity:	ADALIMUMAB (DRUG/TARGET COMPLEX)
Other names:	HUMIRA®
Format:	HRP
Product Type:	Monoclonal Antibody
Clone:	AbD20349_hIgG1
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.

Preparation

Purified IgG prepared by affinity chromatography on Protein A

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.01% Thiomersal

Approx. Protein Concentrations

Total protein concentration 0.1 mg/ml

Immunogen

Adalimumab.

Specificity

Human anti Adalimumab (drug/target complex), clone AbD20349_hIgG1, is an affinity matured, Type 3 antibody that specifically recognizes adalimumab complexed with TNF α . It does not recognize the free drug or unbound TNF α . Clone AbD20349_hIgG1 can be used in assays to measure adalimumab that has been captured via immobilized TNF α , thereby avoiding the bridging assay format. It can also be used to measure the level of the drug/target complex and biosimilar products using bioanalytical assays.

Adalimumab (brand name Humira®) is a human monoclonal antibody (IgG1/kappa) approved for

the treatment of rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis. This therapeutic antibody is directed against the pro-inflammatory cytokine tumor necrosis factor alpha (TNF α), blocking its interaction with the p55 (TNFR1, CD120a) and p75 (TNFR2, CD120b) cell surface TNF receptors, resulting in a down-regulation of the abnormal inflammatory response that is characteristic of autoimmune disease.

[View a summary of all anti-adalimumab antibodies.](#)

Affinity	The monovalent intrinsic affinity of this antibody in an unconjugated format was measured as $K_D=6.7$ nM by real time, label-free molecular interaction analysis on the immobilized adalimumab/TNF α complex.
ELISA	This product is suitable for use in direct ELISA applications. Protocol: PK antigen capture ELISA to measure bound drug exclusively
References	1. Kashiwagi, N. <i>et al.</i> (2017) Method for measuring anti-drug antibody US Patent Application US20170315118A1 2. Harth, S. <i>et al.</i> (2019) Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics. MAbs. 11 (1): 178-190.
Storage	Store at -70°C. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
Guarantee	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Humira® is a registered trademark of Abbott Laboratories.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Related Products

Recommended Useful Reagents

[RECOMBINANT HUMAN TNF ALPHA \(PHP051\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

North & South America Tel: +1 800 265 7376
Fax: +1 919 878 3751

Worldwide Tel: +44 (0)1865 852 700
Fax: +44 (0)1865 852 739

Europe Tel: +49 (0) 89 8090 95 21
Fax: +49 (0) 89 8090 95 50

'M371655:200612'

Printed on 11 Aug 2020
